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ABSTRACT: Protein-protein interactions mediate most physiological and disease processes. Helix-constrained peptides potently 
mimic or inhibit these interactions by making multiple contacts over large surface areas. However, despite high affinities, they typi-
cally have short lifetimes bound to the protein. Here we insert both a helix-inducing constraint and an adjacent electrophile into the 
native peptide ligand BIM to target the oncogenic protein Bcl2A1. The modified BIM peptide bonds covalently and irreversibly to 
one cysteine within the helix-binding groove of Bcl2A1, but not to two other exposed cysteines on its surface, and shows no cova-
lent bonding to other Bcl2 proteins. It also penetrates cell membranes and bonds covalently to Bcl2A1 inside cells. This innovative 
approach to increasing receptor residence time of helical peptides demonstrates the potential to selectively silence a PPI inside cells, 
with selectivity over other nucleophilic sites on proteins. 
Intracellular protein-protein interactions (PPIs) are emerging 
as the most prevalent biological targets for developing new 
therapeutics. However, most PPIs involve large, shallow, sol-
vent-exposed, polar surfaces without hydrophobic pockets for 
accommodating small drug-like compounds. Conventional 
small organic molecule drug discovery has consequently met 
with little success to date in producing effective and selective 
modulators of PPIs.1 On the other hand, peptides present larger 
protein-like surfaces2 and, especially when helix-constrained, 
have shown promise for modulating PPIs inside cells due to 
enhanced potency, and some, albeit limited, cell permeability 
and metabolic stability.3-9 Another drawback of injectable pep-
tide drugs10 is that they often have fast off-rates from their 
target protein,11 contributing to only moderate cell activity at 
µM concentrations. For some small molecule drugs, protein 
ing and duration of drug action have been increased by incor-
porating an electrophile, producing irreversible inhibitors of 
enzymes like kinases.12-14 Historically, this approach has been 
accompanied by off-target side effects due to indiscriminate 
bonding of the electrophile to endogenous nucleophiles.12 
However, in recent years the quest for longer acting drugs 
with greater clinical efficacy has led to a resurgence of cova-
lent drugs, especially with more discriminating and milder 
electrophiles like acrylamides with fewer off-target side ef-
fects.15-18 There are now 42 approved covalent drugs (3 of 27 
approved drugs in 2013 were covalent inhibitors).18 Recently, 
we outlined a computational and design approach to finding 
proteins bearing a nucleophile (e.g. Cys or Lys) located in or 
nearby the binding site of endogenous helical ligands, and to 
designing synthetic helix-constrained peptides bearing an elec-
trophile appropriately positioned to make an optimal covalent 
bond.19 This approach is validated here, extending the scope of 
covalent drugs to peptidomimetics that can modulate PPIs.  
 
Figure 1. PPI targeting by covalent helical peptides. A. Bim pep-
tide (green) bound to Bcl2A1 protein (gray) where a Cys residue 
(yellow) is close to helix-binding site. Bcl2A1 also has two other 
surface Cys residues (PDB: 2VM6). B. Sequence of helix-
constrained peptide 1 (BimSAHBA, full structure in Fig. S1) with 
an indole of Trp2 (green) replaced by an acrylamide electrophile 
(red).19 C. Distance (3.8 Å) between S of Cys55 (yellow) in 
Bcl2A1 and β-carbon of Bim Trp2 (green) can fit a small electro-
phile. D. Helix-constrained peptide (green) first binds non-
covalently to protein (gray), then electrophile (red) in peptide 
bonds covalently to nucleophilic Cys (yellow) in protein. 
 We sought to increase the residence time on an oncogenic 
target protein Bcl2A120 (Fig. 1A) of a helix-constrained pep-
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 tide Bim21,22 (Fig. 1B) by innovatively19 introducing an elec-
trophilic warhead positioned carefully to form a putative cova-
lent bond to sulfur in Cys55 in the target protein (Fig. 1B, 1C).  
 Bcl2A1 is amplified in ∼30% of melanomas and is necessary 
for melanoma growth, with suppression of this gene promot-
ing apoptosis.23 Bcl2A1 is also overexpressed in other types of 
cancer, including leukemias and lymphomas, and induces re-
sistance to chemotherapeutic drugs.23-27 Bcl2A1 binds to BH3-
only proteins, including pro-apoptotic BimBH3 helix.28 Trp2 
of BimBH3 peptide is close to Cys55 in Bcl2A1 (Fig. 1A, 1C), 
enabling potential insertion of an electrophile to make a cova-
lent adduct.20 The idea is that helix-constrained BimBH3 pep-
tide 1 (BimSAHBA, Fig. 1B) forms an initial non-covalent and 
selective interaction with Bcl2 proteins, followed by subse-
quent slower and more specific covalent bonding of a mild 
electrophile, such as acrylamide, to the nearby nucleophilic 
sulfur of Cys55 in the BH3-binding site of Bcl2A1, but not in 
other Bcl2 proteins. Acrylamides are Michael acceptors previ-
ously employed as physiological compatible electrophiles in 
covalent inhibitors, including Ibrutinib, an FDA-approved 
drug acting on B-cell tumours.18  
   An analogue of 1, with diaminopropionic acid (Dap) replac-
ing Trp2, was synthesized on solid phase using on-resin ring 
closing metathesis to create the helix-inducing macrocyclic 
constraint.21 Acrylamide was then attached to the Dap side-
chain affording 2 (Fig. 2 and Fig. S1), which showed similar 
α-helicity to peptide 1 (Fig. S1).  
 
 
Figure 2. Synthesis of electrophilic peptide 2. Grubbs catalyst = 
Benzylidene-bis(tricyclohexylphosphino)-dichlororuthenium. Mtt 
= methyltrityl; * = standard protecting group for Fmoc chemistry. 
S5 = S-2-(4’-pentenyl)alanine (see structure of S5 in Figure S1). 
 
 Reaction of the electrophilic peptide 2 with the Bcl2A1 pro-
tein (Fig. 3) was investigated at different concentrations, 
times, pH and temperature. Formation of the covalent protein 
conjugate 3 was first assessed in a dose-dependent manner at 
pH 7.2 using SDS-PAGE gels (Fig. 3B), producing a single 
higher molecular weight band (>90%) from a ratio as low as 
2:1 (peptide:protein) after 2h at 22°C. Unsurprisingly, the con-
trol peptide (BimSAHBA, 1) did not produce this higher mo-
lecular weight adduct (Fig. 3B) since it has no electrophile.  
 Bcl2A1 has three free Cys residues, so it was necessary to 
confirm that the electrophilic peptide 2 covalently bound only 
to the target Cys55 and not also to one or more of the other 
two surface-exposed Cys residues. Trypsin digestion of the 
single covalent adduct band on the SDS-PAGE gel (Fig. 4A), 
coupled with MS/MS spectral analysis, showed a 1:1 complex 
with an expected fragmentation for a single adduct covalently 
and specifically bound to Cys55 of Bcl2A1 (Fig. 4A). Fur-
thermore, we investigated possible reactions of 2 with other 
proteins of the Bcl2 family (Fig. 4B) and with off-target nu-
cleophiles. As anticipated, SDS-PAGE gel analysis showed no 
covalent reaction of 2 to other Bcl2 proteins (Mcl-1, Bcl-2, 
Bcl-xL), which do not contain a Cys within the BH3 binding 
site. Exposed Cys residues in other regions of these other Bcl2 
proteins also did not bond covalently to 2 (Fig. 4B). Peptide 2 
remained intact and mostly unaffected in 1 mM dithiothreitol 
over several hours (Fig. S2) and displayed similar human se-
rum stability as peptide 1, indicating no significant reaction of 
the electrophile with plasma proteins (Fig. S3). 
Figure 3. Electrophilic peptide 2 bonds covalently to Bcl2A1. A. 
Compound 2 comprises 21 amino acid residues, a helix-
constraining hydrophobic linker, and an acrylamide side chain 
replacing indole of tryptophan. B. Michael addition of 2 to Cys55 
in Bcl2A1. C. Denaturing SDS-PAGE gel analysis shows conju-
gation of Bcl2A1 to 2 (0.5, 2 or 10 equiv. after 2h incubation), but 
not with 1, to form conjugate 3 (see mass spectrum, Fig. 4A). 
Figure 4. Peptide 2 bonds covalently only to Cys55 in Bcl2A1. A. 
MS/MS analysis of trypsin-digested conjugate 3 indicates that 2 
bonds covalently and with specificity to Cys55 in Bcl2A1. The 
digested fragment 4 (expected [M+3H]+3: 872.5) had a MS/MS 
fingerprint showing expected y ion fragments for the Bcl2A1-
derived sequence DNVNVVSVDTAR (red) and the peptide 2-
derived sequence IAQELR (green). No other Cys residue formed 
a covalent adduct. B. Peptide 2 covalently bonds to Bcl2A1 but 
not to other Bcl2 proteins (protein/peptide 1/10 µM, pH 7.2, 5h). 
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  The profile of binding of electrophilic peptide 2 to Bcl2A1 
was assessed by fluorescence polarization (FP) experiments. 
Binding to Bcl2A1 was measured in competition with a 
known fluorescent ligand Bid (FBID, FITC-βA-
DIIRNIARHLAQVGDSMRSI-NH2) that also binds to the 
same BH3-binding site of the protein.29 Peptide 2 was found to 
inhibit Bcl2A1-FBID binding (t1/2 28 min) with complete inhi-
bition by ~90 min (Fig. 5A). At the same Bcl2A1:FBID ratio 
(50:1) where the ligand is saturated with protein, addition of 
non-electrophilic peptide 1 did not significantly interfere with 
the FP signal, suggesting that over this time period peptide 2 
bonds covalently to Bcl2A1. The ligand efficiency was com-
pared for 1 versus 2 in a competitive binding assay against the 
Bcl2A1-FBID complex. A ratio of Bcl2A1:FBID = 3:1 was 
maintained to allow measurable fluorescence. Figure 5B 
shows that 2 was 13-fold more potent in blocking Bcl2A1 
interaction with FBID than the reversible peptide 1 (IC50 after 
2h incubation: 8.5 nM (2) vs 110 nM (1)). This translated to an 
apparent Ki <0.1 nM for 2 and 32 nM for 1 (after 2h). 
 
 
Figure 5. Peptide 2 binds irreversibly to Bcl2A1. Fluorescence 
polarization (FP) measured for Bcl2A1 (A1) binding to fluores-
cent Bid (FBID) in competition with 1 (no electrophile, black) or 
2 (electrophile, green). A. Kinetics for inhibiting formation of 
Bcl2A1-FBID complex measured by FP. FBID (5nM) was satu-
rated with Bcl2A1 (250nM) before adding peptide 1 or 2 (500 
nM) or buffer. B. Competitive FP assay showing inhibition of 
Bcl2A1 (15 nM)-FBID (5 nM) complex by increasing concentra-
tions of 2 or 1 after 2h incubation. C, D. Titration binding curves 
of FBID (5 nM) by Bcl2A1 pretreated with 1 (C) or 2 (D) at dif-
ferent protein:peptide ratio. Addition of buffer instead of peptide 
was used as control (gray, C and D).  
 
 Reversible (Fig. 5C) versus irreversible (Fig. 5D) binding of 
Bcl2A1 to 1 versus 2, respectively, was demonstrated by titra-
tion binding curves in the presence of FBID. A two-fold serial 
dilution of Bcl2A1 (ranging from 250 to 0.25 nM concentra-
tion) was pre-incubated with each peptide at various pro-
tein:peptide ratios (Fig. 5C, 5D). After 1h, the resulting 
Bcl2A1:peptide complex was combined with FBID and FP 
recorded. Peptide 1 did not significantly affect maximum fluo-
rescence measured at high Bcl2A1 concentrations without 
peptide (Fig. 5C), consistent with a reversible inhibitor. In 
contrast, the covalent inhibitor 2 reduced the amount of FBID 
binding and fluorescence in a dose-dependent manner (Fig. 
5D). Full inhibition of Bcl2A1-FBID formation was observed 
after pretreatment with ≥ 2-fold 2 for 2h.  
 Four electrophiles (acrylamide, chloroacetamide, propiol-
amide, cyclopentene-carboxamide) were compared for cova-
lent bonding to Bcl2A1. Incorporated into position 2 of the 
stapled Bim (via the side-chain of a Dap residue) gave pep-
tides 2, 5, 6 and 7 respectively (Fig. 6). Additionally, peptide 8 
was prepared by direct coupling to β-chloroalanine at position 
2.30 Mass spectra (Fig. 6) showed different reactions with 
Bcl2A1, the more powerful electrophiles (5, 6) adding multi-
ple times to Bcl2A1 instead of the 1:1 complex observed for 2. 
On the other hand, electrophiles in 7 and 8 did not bond cova-
lently to Bcl2A1 under the same conditions, possibly due to 
unfavorable positioning of the electrophile (8) or reduced elec-
trophilicity (7).  
Figure 6. Mass spectrometry analysis of protein adducts resulting 
from reacting Bcl2A1 (5 µM) with electrophilic peptides 2 (A), 5 
(B), 6 (C), 7 (D) or 8 (E) (25 µM, pH 7.2, 5h). Structures of elec-
trophilic warheads is shown on left. X = alanine spacer. 
 
 Neither the acrylamide electrophile, nor an appended fluoro-
phore (Fig. 7A), compromised the cell-penetrating capacity of 
the stapled Bim scaffold according to flow cytometry analysis 
(Fig. 7B). Live cell confocal microscopy of U937 lymphoma 
cells incubated with FITC-derived peptide 2 (9, Fig. 7A) es-
tablished cellular uptake of the electrophilic peptide and its 
trafficking to mitochondria, where Bcl2 proteins are predomi-
nantly localized (Fig. 7A).21,22 Next, we investigated whether 
peptide 2 also bonds covalently to Bcl2A1 endogenously ex-
pressed in U937 lymphoma cells (Fig. 7C). Using western 
blot, we confirmed high levels of endogenous Bcl2A1 expres-
sion in this cell line (Fig. S4) which, after lysis, was found to 
bond covalently to 2 as detected by western blot (Fig. 7C). 
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 Additionally, live U937 cells were incubated with 2 (and 1) 
overnight and the extent of covalent conjugation after peptide 
internalization was evaluated by measuring Bcl2A1 modifica-
tion in western blot assays (Fig. 7D). Similar results were ob-
served for HeLa cells overexpressing Bcl2A1 (Fig. S4, S5). 
 
 
Figure 7. Cell uptake, binding and localization of peptides to 
Bcl2A1 in U937 lymphoma cells. A. Live cell confocal microsco-
py of U937 cells with FITC-labelled 9 (1 µM) for 4 h stained for 
nuclei (Hoechst, blue), mitochondria (MitoTracker, red), 9 (green) 
and colocalization of 9 in mitochondria (merge, yellow). B. Flow 
cytometry analysis showing similar cell uptake of 9 (green) com-
pared to a FITC-labelled BimSAHBA 1 (pink). C. Covalent bond-
ing of 2 to Bcl2A1 after 24h incubation at 37°C with U937 cell 
lysates. D. Live U937 cells were incubated with peptides for 24h 
at 37°C, lysed and analyzed by western blot.  
 
 In summary, a Bim peptide analogue 2, fitted with a helix-
inducing constraint and an acrylamide electrophile, was 
demonstrated to bond covalently, irreversibly and specifically 
to Cys55 within the BH3-binding site of the Bcl2A1 protein. 
Importantly, 2 (unlike 5 and 6) did not bond covalently and 
non-specifically to other surface-exposed cysteine residues, 
either in Bcl2A1 or in three other Bcl2 proteins that did not 
have a Cys in the PPI interaction site. Compound 2 was also 
cell permeable and bound to Bcl2A1 in live cells, indicating 
the promise for covalent helical peptides as long acting inhibi-
tors of intracellular protein-protein interactions. This irreversi-
ble binding of inhibitors confers a number of potential ad-
vantages over more conventional reversible inhibitors. A cova-
lent inhibitor-protein complex can more effectively prevent 
competitive binding by other endogenous ligands, anticipated 
to be especially beneficial in the case of Bcl2A1, which also 
interacts with others proteins via its BH3 binding site.24,28 Irre-
versible binding inhibitors do not readily dissociate and so 
their inhibition continues even after the inhibitor leaves the 
circulation, resulting in less frequent and lower doses of drug 
to patients.12 This approach is particularly well suited to pep-
tide-based drugs which are rapidly cleared from the circula-
tion, thereby reducing the chance of non-specific off-target 
bonding of electrophilic peptides. Thus, a traditional liability 
of peptides as drugs can be advantageous in the case of elec-
trophilic drugs. Finally, irreversible covalent bonding peptides 
and peptidomimetics bring the benefit of pharmacological 
silencing of a protein target, likely for the lifetime of the pro-
tein and only terminating with the synthesis of new protein.  
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